Company
Spring Discovery
Last updated Sat May 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
What it does
Spring Discovery uses high-throughput cellular imaging combined with machine-learning models to characterise the "phenotypic signature" of aging at the cellular level, then screens libraries of compounds for those that reverse the signature.
The approach is phenotypic rather than target-based — the hypothesis is that aging is too complex to address one target at a time, so screening for whole-cell rejuvenation signatures finds drugs that conventional target-based discovery would miss.
Founders and funding
Founded 2018 by ex-Google engineers and Stanford-Greg Brockman alumni. Significant Series B funding in 2021. Quiet on public communications; remains in stealth on specific programmes.
Why it matters
Spring is one of several companies betting that AI + phenotypic screening reshapes how aging-modifying compounds are discovered. The broader bet aligns with Insilico Medicine, NewLimit, BioAge, and a growing cluster of AI-first longevity biotechs.